4 research outputs found
Π‘onfirmatory study of the efficacy and tolerability of trifluridine/tipiracil (TAS-102) therapy in the Russian population with chemorefractory metastatic colorectal cancer
Introduction. Trifluridine/Tipiracil (FTD/TPI) is a new chemotherapeutic drug approved in more than 60 countries for use in patients with metastatic colorectal cancer who have registered progression or intolerance to treatment with fluoropyrimi-dines, oxaliplatin and irinotecan, anti-VEGR-and anti-EGFR-targeted agents. This study evaluated for the first time the effectiveness and tolerability of FTD/TPI therapy in the Russian patient population. Materials and methods. A confirmatory open-label single-arm non-randomized trial was conducted in 2 clinical centres in Russia. The main criteria for inclusion were: conduction of at least the 2nd line of standard systemic therapy for metastatic colon adenocarcinoma. The primary efficacy criteria were: 2-month progression-free survival; secondary β median progression-free survival, disease control frequency, safety assessment, overall survival. Research number: NCT03274882. Results. A total of 26 patients were included in the study; the median age was 60.5 years (30 to 78); 19 (73%) women; and 4 patients with ECOG 0 and 22 β with ECOG 1. All patients were previously treated with the inclusion of oxaliplatin, irinotecan, fluoropyrimidines, 21 (81%) β bevacizumab, 6 (23%) β anti-EGFR antibodies, and 2 (7.7%) β regorafenib. The median for treatment courses was 4 (1β21), 11 (42.3%) patients were treated for 6 months or more. The two-month progression-free survival rate was 52% with a median progreesion-free survival rate of 4 months (95% CI 1.8β7.4 months). The median of total survival rate was 11 months (95% CI 5,2β16,8 months). Disease control was achieved in 60%. Neutropenia, nausea, vomiting, anemia, weakness prevailed among undesirable events associated with treatment (β₯5 patients). The majority of complications were of the 1stβ2nd degree. Among the undesirable events of the 3rdβ4th degree, neutropenia was more common, while in 3 patients febrile neutropenia of the 3rd degree was registered. Conclusions. In the Russian population of patients with colorectal chemorefractory cancer, the drug FTD/TPI (TAS-102) shows efficacy and tolerability comparable to the RECOURSE registration study. Β© 2020, Remedium Group Ltd. All rights reserved
Π‘ΡΠ°Π²Π½Π΅Π½ΠΈΠ΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² Π»Π΅ΡΠ΅Π½ΠΈΡ Π±ΠΎΠ»ΡΠ½ΡΡ Π½Π΅ΠΎΠΏΠ΅ΡΠ°Π±Π΅Π»ΡΠ½ΡΠΌ Π½Π΅ΠΌΠ΅Π»ΠΊΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠΌ ΡΠ°ΠΊΠΎΠΌ Π»Π΅Π³ΠΊΠΎΠ³ΠΎ Π² ΡΠ°ΠΌΠΊΠ°Ρ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ ΠΈ ΡΡΠ°Π½Π΄Π°ΡΡΠ½ΠΎΠΉ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΡΠ°ΠΊΡΠΈΠΊΠΈ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΏΡΠ΅Π²Π΄ΠΎΡΠ°Π½Π΄ΠΎΠΌΠΈΠ·Π°ΡΠΈΠΈ
Rationale: Non-small cell lung cancer (NSCLC) is an aggressive disease with median survival of 1214 months in inoperable patients in the pre-immunotherapy era. Nowadays, under treatment with checkpoint inhibitors median survival is 1922 months. However, only a proportion of patients are sensitive to immune therapy. In this regard, inclusion into clinical trials remains a priority option for patients from medical perspective.
Aim: To compare the results in NSCLC patients treated in accordance with the current clinical guidelines and in international clinical trials using the propensity score matching.
Materials and methods: The study included data from 344 patients with histologically verified unresectable advanced NSCLC without activating mutations, who received the 1st line systemic medical therapy at various combinations (single agent chemotherapy, platinum doublet-based therapy, chemoimmunotherapy, single agent immunotherapy) within the compulsory health insurance (CHI), and from 90 patients, who received therapy in clinical trials. A direct comparison of long-term treatment results was carried out with the log-rank method. To exclude any influence of individual factors on survival rates, an univariate regression analysis and pseudorandomization accounting for these factors were carried out.
Results: The direct comparison of the treatment results showed a higher progression-free survival rate in the patients treated according to clinical trial protocols, than in those treated under CHI (13.3 [95% confidence interval (CI) 8.118.5] months vs 6.4 [95% CI 5.96.9] months). Pseudorandomization of patients based on a combination of statistically significant parameters from the CHI and clinical trial groups showed a significantly longer time to progression in the trial group (13.3 [95% CI 8.318.3] vs 6.3 [95% CI 4.87.7] months).
Conclusion: Participation in clinical trials is per se a factor that can significantly impact the longer duration of the treatment effect. This indicates the necessity of the most active use of this tool in clinical practice.ΠΠΊΡΡΠ°Π»ΡΠ½ΠΎΡΡΡ. ΠΠ΅ΠΌΠ΅Π»ΠΊΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠΉ ΡΠ°ΠΊ Π»Π΅Π³ΠΊΠΎΠ³ΠΎ (ΠΠΠ Π) Π°Π³ΡΠ΅ΡΡΠΈΠ²Π½ΠΎΠ΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠ΅ Ρ ΠΌΠ΅Π΄ΠΈΠ°Π½ΠΎΠΉ Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΠΈ Ρ Π½Π΅ΠΎΠΏΠ΅ΡΠ°Π±Π΅Π»ΡΠ½ΡΡ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π² Π΄ΠΎΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΡΡ ΡΠΏΠΎΡ
Ρ 1214 ΠΌΠ΅ΡΡΡΠ΅Π². Π‘Π΅Π³ΠΎΠ΄Π½Ρ Π½Π° ΡΠΎΠ½Π΅ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠ°ΠΌΠΈ ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΡΡ
ΡΠΎΡΠ΅ΠΊ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΠΈ Π²ΠΎΠ·ΡΠΎΡΠ»ΠΈ Π΄ΠΎ 1922 ΠΌΠ΅ΡΡΡΠ΅Π², ΠΎΠ΄Π½Π°ΠΊΠΎ Π»ΠΈΡΡ ΡΠ°ΡΡΡ Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½Π° ΠΊ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ. Π ΡΡΠΎΠΉ ΡΠ²ΡΠ·ΠΈ Π²ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅ Π² ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΎΡΡΠ°Π΅ΡΡΡ Π΄Π»Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΏΡΠΈΠΎΡΠΈΡΠ΅ΡΠ½ΡΠΌ Π²Π°ΡΠΈΠ°Π½ΡΠΎΠΌ Ρ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠΉ ΡΠΎΡΠΊΠΈ Π·ΡΠ΅Π½ΠΈΡ.
Π¦Π΅Π»Ρ ΡΡΠ°Π²Π½Π΅Π½ΠΈΠ΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΠΠ Π Π² ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΠΈΠΈ Ρ ΡΠ΅ΠΊΡΡΠΈΠΌΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°ΡΠΈΡΠΌΠΈ ΠΈ Π² ΡΠ°ΠΌΠΊΠ°Ρ
ΠΌΠ΅ΠΆΠ΄ΡΠ½Π°ΡΠΎΠ΄Π½ΡΡ
ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΏΡΠ΅Π²Π΄ΠΎΡΠ°Π½Π΄ΠΎΠΌΠΈΠ·Π°ΡΠΈΠΈ (Π°Π½Π³Π». propensity score matching).
ΠΠ°ΡΠ΅ΡΠΈΠ°Π» ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠ΅Π½Ρ Π΄Π°Π½Π½ΡΠ΅ ΠΎ 344 Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈ Π²Π΅ΡΠΈΡΠΈΡΠΈΡΠΎΠ²Π°Π½Π½ΡΠΌ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΡΠΌ Π½Π΅ΡΠ΅Π·Π΅ΠΊΡΠ°Π±Π΅Π»ΡΠ½ΡΠΌ ΠΠΠ Π Π±Π΅Π· Π°ΠΊΡΠΈΠ²ΠΈΡΡΡΡΠΈΡ
ΠΌΡΡΠ°ΡΠΈΠΉ, ΠΏΠΎΠ»ΡΡΠ°Π²ΡΠΈΡ
1-Ρ Π»ΠΈΠ½ΠΈΡ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠΉ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π² ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΡΡ
(ΠΌΠΎΠ½ΠΎΡ
ΠΈΠΌΠΈΠΎΡΠ΅ΡΠ°ΠΏΠΈΡ, ΡΠ΅ΡΠ°ΠΏΠΈΡ Π½Π° ΠΎΡΠ½ΠΎΠ²Π΅ ΠΏΠ»Π°ΡΠΈΠ½ΠΎΠ²ΡΡ
Π΄ΡΠΏΠ»Π΅ΡΠΎΠ², Ρ
ΠΈΠΌΠΈΠΎΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΡ, ΠΌΠΎΠ½ΠΎΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΡ) ΠΏΠΎ ΠΏΡΠΎΠ³ΡΠ°ΠΌΠΌΠ΅ ΠΎΠ±ΡΠ·Π°ΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠ³ΠΎ ΡΡΡΠ°Ρ
ΠΎΠ²Π°Π½ΠΈΡ (ΠΠΠ‘), ΠΈ 90 Π±ΠΎΠ»ΡΠ½ΡΡ
, ΠΏΠΎΠ»ΡΡΠ°Π²ΡΠΈΡ
ΡΠ΅ΡΠ°ΠΏΠΈΡ Π² ΡΠ°ΠΌΠΊΠ°Ρ
ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ. ΠΡΡΠΌΠΎΠ΅ ΡΡΠ°Π²Π½Π΅Π½ΠΈΠ΅ ΠΎΡΠ΄Π°Π»Π΅Π½Π½ΡΡ
ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΎ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ log-rank. Π‘ ΡΠ΅Π»ΡΡ ΠΈΡΠΊΠ»ΡΡΠ΅Π½ΠΈΡ Π²Π»ΠΈΡΠ½ΠΈΡ ΠΎΡΠ΄Π΅Π»ΡΠ½ΡΡ
ΡΠ°ΠΊΡΠΎΡΠΎΠ² Π½Π° ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΠΈ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Ρ ΠΌΠΎΠ½ΠΎΡΠ°ΠΊΡΠΎΡΠ½ΡΠΉ ΡΠ΅Π³ΡΠ΅ΡΡΠΈΠΎΠ½Π½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΈ ΠΏΡΠ΅Π²Π΄ΠΎΡΠ°Π½Π΄ΠΎΠΌΠΈΠ·Π°ΡΠΈΡ Ρ ΠΈΡ
ΡΡΠ΅ΡΠΎΠΌ.
Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΡΠΈ ΠΏΡΡΠΌΠΎΠΌ ΡΡΠ°Π²Π½Π΅Π½ΠΈΠΈ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π½ΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΡ Π±Π΅Π· ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π±ΡΠ»Π° Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎ Π²ΡΡΠ΅ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², Π»Π΅ΡΠ΅Π½Π½ΡΡ
ΠΏΠΎ ΠΏΡΠΎΡΠΎΠΊΠΎΠ»Π°ΠΌ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ, ΡΠ΅ΠΌ ΠΏΠΎ ΠΏΡΠΎΠ³ΡΠ°ΠΌΠΌΠ΅ ΠΠΠ‘, 13,3 ΠΌΠ΅Ρ. (95% Π΄ΠΎΠ²Π΅ΡΠΈΡΠ΅Π»ΡΠ½ΡΠΉ ΠΈΠ½ΡΠ΅ΡΠ²Π°Π» (ΠΠ) 8,118,5) ΠΏΡΠΎΡΠΈΠ² 6,4 ΠΌΠ΅Ρ. (95% ΠΠ 5,96,9). ΠΠΎΡΠ»Π΅ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ ΠΏΡΠ΅Π²Π΄ΠΎΡΠ°Π½Π΄ΠΎΠΌΠΈΠ·Π°ΡΠΈΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΎΠΊΠ°Π·Π°Π»ΠΎΡΡ, ΡΡΠΎ Π²ΡΠ΅ΠΌΡ Π΄ΠΎ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΎΡΡΠ°Π²Π°Π»ΠΎΡΡ Π±ΠΎΠ»ΡΡΠ΅ Π² Π³ΡΡΠΏΠΏΠ΅ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ: 13,3 (95% ΠΠ 8,318,3) ΠΈ 6,3 ΠΌΠ΅Ρ. (95% ΠΠ 4,87,7) ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ.
ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π£ΡΠ°ΡΡΠΈΠ΅ Π² ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡΡ
ΡΠ²Π»ΡΠ΅ΡΡΡ per se ΡΠ°ΠΊΡΠΎΡΠΎΠΌ, ΠΊΠΎΡΠΎΡΡΠΉ ΠΌΠΎΠΆΠ΅Ρ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠΌ ΠΎΠ±ΡΠ°Π·ΠΎΠΌ Π²Π»ΠΈΡΡΡ Π½Π° ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΠ΅ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ ΡΡΡΠ΅ΠΊΡΠ° ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π½ΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ, ΡΡΠΎ ΡΠΊΠ°Π·ΡΠ²Π°Π΅Ρ Π½Π° Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎΡΡΡ ΠΌΠ°ΠΊΡΠΈΠΌΠ°Π»ΡΠ½ΠΎ Π°ΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ ΡΡΠΎΠ³ΠΎ ΠΈΠ½ΡΡΡΡΠΌΠ΅Π½ΡΠ° Π² ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΡΠ°ΠΊΡΠΈΠΊΠ΅